Long-term follow-up data from the phase III KATHERINE study in people with HER2-positive early-stage breast cancer who have residual invasive disease following neoadjuvant treatment showed that a statistically significant and clinically meaningful improvement in overall survival, a secondary endpoint, was observed with adjuvant Kadcyla (ado-trastuzumab emtansine) compared to Herceptin (trastuzumab).
Researchers at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences have been awarded five grants from NCI in 2024, totaling $4.6 million.
